While reporting its financial results for the fourth quarter on Thursday, Regeneron Pharmaceuticals Inc. (REGN) said it is continuing to work constructively with Sanofi (SNYNF, SNY) to finalize its modified antibody agreement for Praluent and Kevzara, which it expects to be accretive in 2020.
from RTT - Earnings https://ift.tt/2HbXIdn
via IFTTT
No comments:
Post a Comment